Last reviewed 2026-04-22 · How we verify

CyclASol Ophthalmic Solution

CyclASol is a cyclosporine A ophthalmic emulsion that suppresses local immune responses in the eye to reduce inflammation and improve tear production in dry eye disease.

CyclASol is a cyclosporine A ophthalmic emulsion that suppresses local immune responses in the eye to reduce inflammation and improve tear production in dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca).

At a glance

Mechanism of action

Cyclosporine A is a calcineurin inhibitor that blocks T-cell activation and reduces pro-inflammatory cytokine production in ocular tissues. By suppressing the immune-mediated inflammation characteristic of dry eye disease, it helps restore tear film stability and reduce ocular surface damage. The CyclASol formulation uses a proprietary submicron emulsion technology to enhance corneal penetration and bioavailability.

Approved indications

• Dry eye disease (keratoconjunctivitis sicca)

Common side effects

• Ocular irritation or burning
• Conjunctival hyperemia
• Eye discomfort

Key clinical trials

• CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 (PHASE3)
• ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (PHASE3)
• CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (PHASE2, PHASE3)
• CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) (PHASE2)
• CyclASol® Phase 1 Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CyclASol Ophthalmic Solution CI brief — competitive landscape report
• CyclASol Ophthalmic Solution updates RSS · CI watch RSS
• Novaliq GmbH portfolio CI